America Great Health

America Great Health operates as a biotechnology company in the United States. It focuses on the research and development of protein and peptide small molecular drugs; and the manufacturing and sale of AI cloud computing-based diagnostic and medical devices, cell therapy, and regenerative medicine and supplements. The company was formerly known as Crown Marketing and changed its name to America Great Health in March 2017. America Great Health was founded in 2013 and is headquartered in Alhambra, California.

America Great Health trades as AAGH on OTC. The company is classified in Healthcare / Biotechnology and reports in USD.

The current profile places the business in Biotechnology. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $391,743 of revenue and -$721,242 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

America Great Health can be compared against peers such as Ayala Pharmaceuticals, Inc., Algernon Pharmaceuticals Inc., Agentix Corp., Appili Therapeutics Inc., Health Sciences Group, Inc., Universal Ibogaine Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $2.12M, beta of 5.21, and return on equity of +12.6%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

AAGH currently shows total debt of $2.84M and beta of 5.21. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 10-Q (2026-06-04 00:00:00), 10-K (2026-04-10 00:00:00), NT 10-K (2025-09-29 00:00:00), 8-K (2025-09-15 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.americagreathealth.us

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.